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a decrease (15.3%) in LC frequency,
whereas there was no change in LC
numbers following administration of
TNF-a (200U; data not shown). Con-
versely, and as expected, both IL-1b
and TNF-a induced LC migration in a
healthy individual (decreases of 11.4
and 21.6%, respectively).
These results reveal a marked differ-
ence in the mobilization of epidermal
LCs in early-onset compared with late-
onset psoriasis. In early-onset psoriasis,
LCs within PN sites respond to neither IL-
1b nor TNF-a, whereas in late-onset
psoriasis, LCs are responsive to IL-1b
but not TNF-a. This failure of exogenous
TNF-a to mobilize LCs does not necessa-
rily reflect unresponsiveness to TNF-a per
se. As LC migration requires the receipt
of signals from both TNF-a and IL-1b,
unresponsiveness in this instance could
be secondary to an impairment of IL-1b
production, bioactivation, and/or signal-
ling. The mechanistic basis for these
important differences in LC migration is
presently unresolved, but is the focus of
current investigations. However, even in
the absence of an appreciation of how
such differential regulation is effected,
the variable mobilization of LCs between
these two forms of psoriasis is striking.
Although not yet exhaustive, these
analyses provide intriguing indications
of important differences in LC function
between early- and late-onset psoriasis.
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TO THE EDITOR
TRPA1 (transient receptor potential
cation channel subfamily A, member 1
(ANKTM1: Ankyrin-like transmem-
brane domains 1)) was first discovered
in nociceptive sensory neurons from
dorsal root ganglia, as one of the
transient receptor potential (TRP) cha-
nnels activated by temperature below
17 oC (Story et al., 2003). Intracellular
calcium elevation and electrical activity
were observed at 17 1C (Story et al.,
2003). TRPA1 is also activated by allyl
isothiocyanate (Jordt et al., 2004) and
cinnamaldehyde (Bandell et al., 2004).
Both reagents induce the elevation of
intracellular calcium and electrical
activity of sensory neurons (Bandell
et al., 2004; Jordt et al., 2004). 2-(1,
3-Dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-
7H-purin-7-yl)-N-(4-isopropylphenyl)ace-
tamide (HC030031) was reported to
be a selective TRPA1 channel blocker
(McNamara et al., 2007). The effect
was examined in human embryonic
kidney 293 cell lines stably expressing
TRPA1, and the IC50 value of HC030031
against allyl isothiocyanate-induced acti-
vation was 6.2mM (McNamara et al.,
2007).
Recently, expression of TRPA1 in
human epidermis was reported (Atoyan
et al., 2009). The involvement of TRP
channels in sensitive skin was sug-
gested (Stander et al., 2009), and
TRPA1 was found to mediate formalin-
induced pain (McNamara et al., 2007).
Abbreviations: HC030031, 2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(4-
isopropylphenyl)acetamide; TRP, transient receptor potential; TRPA1, transient receptor potential cation
channel subfamily A, member 1
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The putative role of TRPA1 in cuta-
neous sensation in the peripheral ner-
vous system and in keratinocytes might
have important implications for the
medication of itching and other abnor-
mal skin sensitivities.
In this study, we examined the effect
of the TRPA1 agonist or antagonist on
epidermal permeability barrier homeo-
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Figure 1. Effects of topical application of activators and inhibitors of TRPA1 receptor. (a) Topical application of TRPA1 agonists accelerated permeability
barrier recovery after tape stripping and pre-treatment with a TRPA1 antagonist, HC030031, blocked the recovery. (b) Cold exposure for 1minute accelerated
barrier recovery after tape stripping, and this effect was blocked by pre-treatment with a TRPA1 antagonist, HC030031. (c) Topical application of bradykinin
accelerated the barrier recovery and it was blocked by HC030031. Topical application of HC030031 alone delayed the barrier recovery. F¼ 120.38,
Po0.0001. Al, allylisothiocyanate; CA, cinnamaldehyde; CNT, control; HC, HC030031; NS, not significant.
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stasis. We also investigated the effect of
a brief exposure to cold on the barrier
recovery rate.
First, we evaluated the effects of
TRPA1 agonists on the intact skin of
hairless mice. We disrupted the
permeability barrier by tape stripping,
and immediately applied 100ml of
agonist solution. Topical application of
allyl isothiocyanate (0.5mM) or cinna-
maldehyde (0.5mM) accelerated the
barrier recovery, and the effect of both
agents was blocked by pre-treatment
with HC030031 (50 mM; Figure 1a).
We next cooled (10–15 1C) the skin
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Figure 2. Immunohistochemical study of mouse skin with TRPA1 antibody. (a) Immunoreactivity to TRPA1 antibody was observed throughout the mouse
epidermis. (b) In negative control (without antibody), an artifactual red color was observed on the stratum corneum (SC). No immunoreactivity was observed in
the epidermis. (c, d) Merged image of a and b with Nomarski differential interference contrast image and Hoechst33528 staining. Bar¼ 50mm. (e) Western
immunoblot analysis with TRPA1 antibody of protein extract from hairless mouse epidermis. Bands appeared at 115 kDa in both cases. (g) Electron-microscopic
observation of skin after brief cold exposure. A thick intercellular lipid domain (asterisks) was observed between the SC and SG of the skin after a brief cold
exposure (untreated control: f, arrows indicate exocytosis of lamellar bodies). (h) Pre-treatment with HC030031 reduced the lamellar body secretion (asterisks)
(f, g, h: bar¼100nm). Large numbers of secreted lamellar bodies were observed between the SC and SG of the brief cold-exposed skin fixed with ruthenium tetroxide
(i: bar¼ 20nm). The results of quantification are shown in j. The intercellular lipid domain of cold-exposed skin became significantly larger than that of the control,
and pre-treatment with HC030031 blocked this change. DRG, proteins from rat dorsal root ganglion; Epi, proteins from mouse epidermis.
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surface of one flank for 1minute with a
cold insulator. The other flank was kept
at 35–36 1C with a heat pad. The
temperature on both sides was mon-
itored using a thermometer (for details,
see Methods in Supplementary Material
online). One minute of cooling accel-
erated the barrier recovery and this
effect was blocked by pre-treatment
with HC030031 (Figure 1b). Shorter
periods of cold exposure (10, 30 sec-
onds) did not significantly influence the
recovery rate (data not shown).
It has been shown that TRPA1 is also
activated by an endogenous inflammatory
peptide, bradykinin (Bandell et al., 2004).
Topical application of bradykinin accel-
erated the barrier recovery and it was
blocked by HC030031. Application of
HC030031 alone delayed the barrier
recovery (Figure 1c). We speculated that
endogenous bradykinin might be released
by barrier disruption and HC030031
might block the effect of the endogenous
factor on TRPA1. TRPA1 might thus act as
a sensor of barrier insult, serving to trigger
the barrier recovery process. We evalu-
ated the histological alteration by light-
microscopic and electro-microscopic ob-
servation. The skin treated with
HC030031 did not indicate any specific
sign of toxicity of the reagent.
Immunohistochemical study reve-
aled positive immunostaining for
TRPA1 on mouse epidermis (Figure 2a
and c, negative control: b and d).
Western blotting of the epidermis from
hairless mice with TRPA1 antibody
revealed a band of the expected mole-
cular weight (115 kDa; Figure 2e; Dai
et al., 2007).
An electron-microscopic evaluation
indicated that brief cold exposure
accelerated lamellar body secretion at
the stratum corneum–stratum granulo-
sum interface (Figure 2g and f: control),
and this enhanced secretion was
blocked by pretreatment with
HC030031 (Figure 2h). Figure 2i shows
secreted lamellar bodies in the skin
exposed to low temperature. The results
are quantified in Figure 2j. After the
barrier disruption by acetone treatment,
cold exposure accelerated the barrier
recovery and it was blocked by
HC030031 (data not shown).
The mechanism of the effect of
TRPA1 agonists and antagonists on skin
barrier homeostasis has not been clari-
fied by this study. Activation of TRP
receptors might induce unknown elec-
tro-physiological effects in epidermal
keratinocytes. In connection with the
sensation of warm and cold in the
peripheral nervous system, mechano-
activated potassium channel TREK-1
(Twik-related K(þ ) channel) and
TRAAK (Twik-related arachidonic acid-
stimulated K(þ ) channel; Twik: Tandem
of p domains in a weak inward rectifying
K(þ ) channel)) influenced the function
of TRP channels (Noel et al., 2009).
These channels are expressed in HaCaT
cells, spontaneously immortalized hu-
man keratinocyte line (Kang et al.,
2007). Interactions between these po-
tassium receptors and TRP channels
should lead to a better understanding
of the function of TRP channels in
epidermal keratinocytes.
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TO THE EDITOR
The thermo-sensitive protein transient
receptor potential cation channel sub-
family A, member 1 (TRPA1) is activated
by temperatures below 17 oC and by
several reagents, including allyl isothio-
cyanate and cinnamaldehyde (Dhaka
et al., 2006). Recently, expression of
TRPA1 in human epidermis was reported
(Atoyan et al., 2009). Thus, epidermal
keratinocytes might have a sensoryAbbreviations: TRPA1, transient receptor potential cation channel subfamily A, member 1
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